Welcome to our dedicated page for BridgeBio Oncology Therapeutics SEC filings (Ticker: BBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotechnology companies file extensive documentation with the SEC, and BridgeBio Oncology Therapeutics (BBOT) is no exception. Understanding these filings provides insight into the company's pipeline progress, cash position, and strategic direction—critical factors for oncology biotech investors.
BBOT's 10-K annual reports detail research and development expenditures, clinical trial progress, and the company's financial runway. For a pre-revenue biotechnology company, the balance sheet and cash burn rate disclosed in quarterly 10-Q filings indicate how long the company can fund operations before requiring additional capital.
Form 8-K filings from BridgeBio Oncology often announce material events including clinical data releases, regulatory updates, and corporate transactions. These current reports provide timely information about pipeline developments that may not appear in periodic filings for months.
Proxy statements reveal executive compensation structures and board composition, while Form 4 insider transaction filings show when company executives and directors buy or sell BBOT shares. Our AI-powered summaries help you quickly understand complex biotechnology disclosures without reading hundreds of pages of technical documentation.
BridgeBio Oncology Therapeutics, Inc. reported an update to its Chief Executive Officer and director’s stock option grant. On December 10, 2025, the company rescinded 1,114,400 stock options from an option grant originally dated October 2, 2025, as an exempt disposition to the issuer under Rule 16b-3.
After this change, 500,000 stock options from the original grant remain outstanding, each with an exercise price of $12.44 and an expiration date of October 1, 2035. The options vest in 48 substantially equal monthly installments beginning on the monthly anniversary of October 2, 2025, as long as the reporting person continues to provide service to the company on each vesting date.
BridgeBio Oncology Therapeutics (BBOT) filed its Q3 2025 10‑Q, highlighting a post‑de‑SPAC balance sheet and higher operating spend as programs scale. Cash and cash equivalents were $408.7 million and short‑term marketable securities were $59.5 million, for total liquidity of $468.3 million as of September 30, 2025. The company reported a net loss of $44.8 million for the quarter as operating expenses reached $49.2 million (R&D $35.1 million; G&A $14.1 million), with interest income of $3.4 million and $1.0 million from a transition services agreement.
BBOT completed its de‑SPAC on August 11, 2025, including a $260.9 million PIPE and $120.9 million from the SPAC trust, and ended the quarter with 79,196,710 shares outstanding. For the nine months, net loss was $95.2 million as the company advanced RAS and PI3K oncology programs and established public‑company infrastructure. Management states existing cash, cash equivalents, and marketable securities are expected to support operations for at least one year from issuance.
BridgeBio Oncology Therapeutics (BBOT) furnished an 8-K to announce it issued a press release with financial results for the quarter ended September 30, 2025. The company states the press release is provided under Item 2.02 and is being furnished, not filed, meaning it is not subject to Section 18 liabilities of the Exchange Act. The filing includes Exhibit 99.1 (the press release dated November 12, 2025) and Exhibit 104 (the cover page Inline XBRL data).
BridgeBio Pharma LLC, together with BridgeBio Pharma, Inc., reported acquiring 784,720 shares of BridgeBio Oncology Therapeutics, Inc. (BBOT) common stock on 10/10/2025 under transaction code J.
The shares were issued pursuant to an amendment to the Transition Services Agreement dated August 11, 2025, in exchange for additional financial and accounting support services provided through December 31, 2025.
After the transaction, 14,589,846 shares were beneficially owned. The shares are held by BridgeBio Pharma LLC, with voting and investment power exercised by its parent, BridgeBio Pharma, Inc. The reporting persons and directors disclaim beneficial ownership except to any pecuniary interest. The reporting person is identified as a director, and the form was filed by more than one reporting person.
BridgeBio Oncology Therapeutics, Inc. filed a Form S-8 to register securities under several employee benefit plans following corporate changes that include a domestication to Delaware and a name change. The filing discloses that TheRas, Inc. merged into a Merger Sub, leaving TheRas as a direct, wholly owned subsidiary, and that an Inducement Plan was adopted by the board under Nasdaq Rule 5635(c)(4) without stockholder approval. The registration references prior filings including the Form 10-K for year ended December 31, 2024 and subsequent 10-Qs, and incorporates the company’s Certificate of Incorporation and Bylaws by reference. Exhibits listed include the 2025 equity plans, the 2016 TheRas plan, legal opinions, auditor consents, and a filing-fee table. Signature blocks show directors and dates of October 10, 2025.
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported a Form 4 disclosing that Eli M. Wallace, who serves as Chief Executive Officer and a director, was granted a stock option on
FAQ
What is the current stock price of BridgeBio Oncology Therapeutics (BBOT)?
What is the market cap of BridgeBio Oncology Therapeutics (BBOT)?
